---
title: "Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Guidelines questions"
description: "Guidelines questions on Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Questions: What do NCCN guidelines say about continuing covalent BTK inhibitors such as Imbruvica? 1 question quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/guidelines"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Imbruvica (ibrutinib) in chronic lymphocytic leukemia and small lymphocytic lymphoma: Guidelines questions

Manufacturer: Pharmacyclics LLC; Janssen Biotech, Inc.  
Prescribing information: [Imbruvica](https://www.rxabbvie.com/pdf/imbruvica_pi.pdf)

Questions that apply to every indication of Imbruvica are on [Imbruvica (ibrutinib), all indications](https://www.evicenter.com/medical-information/imbruvica).

## Guidelines

<a id="imbruvica-nccn-continuation"></a>

### What do NCCN guidelines say about continuing covalent BTK inhibitors such as Imbruvica?

> “In patients with no intolerance, cBTKi can be continued until disease progression, while following recommended dose modification guidance as needed
>
> See NCCN Guidelines<sup>®</sup> for the complete list of recommendations.”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=In%20patients%20with%20no%20intolerance%2C,the%20complete%20list%20of%20recommendations.)

> “NCCN Guidelines recommend continuation of the same cBTKi until progression and/or intolerance<sup>2</sup>”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=NCCN%20Guidelines%20recommend%20continuation%20of%20the%20same%20cBTKi%20until%20progression%20and%2For)

> “NCCN makes no warranties of any kind whatsoever regarding their content, use, or application, and disclaims any responsibility for their application or use in any way.”

Source: [IMBRUVICA: Dosing Modifications - CLL/SLL, captured 2026-11-13](https://www.imbruvicahcp.com/cll/dosing/dosing-modifications-for-adverse-reactions#:~:text=NCCN%20makes%20no%20warranties%20of,or%20use%20in%20any%20way.)

Note: The statements concern covalent BTK inhibitors (cBTKi) as a class. The page cites the NCCN Clinical Practice Guidelines in Oncology for CLL/SLL, Version 1.2026.

## Related pages
- [Medical information: Imbruvica (ibrutinib): Chronic lymphocytic leukemia and small lymphocytic lymphoma](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma)
- [Indication](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/safety)
- [Specific populations](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/imbruvica--chronic-lymphocytic-leukemia-and-small-lymphocytic-lymphoma/access-and-coverage)
